Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
����� ������
�������2020�8�
:Y�$cÊ#��
2
• :Y�%�Q[�w$��N$(2WM!��eA �l��*$ �/�7:9�U9'�%�1tj$=�$T¥#��0����$c�ÆÌ'�%u��Æ̼2¡l�0*$ %�/'�3�U9�7:9'�%�1tj$=�$T¥#���·\TÂ#~��²«*��%É<'�%�1.$È°2s��#�eA$����$Ç�'�%¨u2?�!% �'�3�
• :Y�#�Å�1�0�w%�oJp$^x��h�PE¼$�2K�!��'� ��$�Xk�r�k'�%º]k#���eA%¦.`S'�%Z��0*$ %�/'�3�:Y�#�Å�1��w%�@K#R��0�!"��½�10�! �/'��:Y��-&�$�ÅN�#���eA$��#-0@K$Hi"�#�¦;*�¸$WM aV'�%v\�0�!% �'�3�:Y�#�Å�1�µn$>¹#Q�0�®%�µn�w ��µn�w#%��q�0���zf�0���y��0���dÃ2*����f¤�0���z§�0���zÁ�0�'�%���k �0�!-"`o�-&µn$@>�_�>¹�<n@+�2¢S�0�$¸´Í��`o2©('���1.#�L�10*$ %�/'�3��µn�w%�o�ID��"�w2*!#��eA$^�¿${�#~��'���$�)��1.$µn�w%�¬�"654+b�Lg¾#±³�1�X}$>¹%µn�w#S�'�%Î��1�*$!%8¯#»"0EB �/'���� ���µn�w#]�M#ÄÀ�0�!$"-�£i����O�"�w�µn$<n@+�$¸$GF#Ë.���µnz§#Q�0�®2�½'�%Ïr�0=�$ m2eA%�'�3�
• :Y�$�l#��/�eA%eA ID��"�.,0�w$�Xk�r�k+º]k#ÄÀ��K�!��'��eA%��0�w$�Xk�r�k�0%º]k#��ªC$|�2?���.���$�Xk�r�k�0%º]k#���eA%¦.`S¶&Z��0*$ %�/'�3�
• :Y�#�Å�1��w%�@K#R��0�!"��½�10�! �/'��
��
3
1. ����
2. ��� ��
3. ��������
4. ������
5. ����
• Appendix
����
4
DNÇrModalis Therapeutics�CRISPR�¢�5�'�w^���¸¯[�²5?+9�
5
DN� ��DN8*<'
w^ 2016B1P�RqAmS5?+9��
knO knoÃ�CEO QÆÁ
DNu�T Rq~G¶�@E�ËI16-5 Y’s1=4F
aC_F Modalis Therapeutics Inc. (51 Moulton st. Cambridge MA)
MJÇr CRISPR�¢�h�§µ�bS�4;,02!�7�¢�©
fEL 1,300,000�]
ɬi¨� 41.1�]
SK���| 25,100,000�(È���2,903,200�³ )
·J`| 17�(g��2020B5P31@x�����PhD 7��[CZ]4� [}t]13��
{Âľ J-STARTUP�X�2018B�
�JÇr�Çr�Å£
BP ţ
2016B1P Rq~G¶�� /�&�?��DN�x ��DN8*<'��w^
2016B4P aC6$+:�(,-�#?3<,&\�g�[DNEdiGENE Inc.�x Modalis Therapeutics Inc.��w^
2017B4P �'.;'�µ��DN��W��CRISPR-GNDM�h��U¦®ºj�Ã�
2017B12P ¤�2�=7��DN�»|N�z{����Hfºj�Ã�
2017B12P �'.;'�µ��DN��W�´A�U¦®ºj�Ã�
2018B6P l�sJ��±y��')�0�,4�J�¥v��4>";7�J-Startup�cX
2019B1P pN�Rq~G¶�Z� �
2019B3P �'.;'�µ��DN��W�¸¯[�²µbS�;�(?'ºj�Ã�
2019B3P aC[DN�aC6$+:�(,-�#?3<,&\Z� ��´¡
2019B8P
�¼���DN8*<'�°�n��Modalis Therapeutics Corporation���¿UV�aC[DNEdiGENE Inc.�N��Modalis Therapeutics Inc.��¿
2019B9P �'.;'�µ��DN��W�¸¯[�²µbS�2ªd���;�(?'ºj�Ã�
2019B11P �%���DN��W��CRISPR-GNDM�h��U¦®ºj�Ã�
2020B4P Editas Medicine, Inc.��W�CRISPR/Cas9�½�¹«ÀYe��½Ê�{��;�(?'ºj�Ã�
Modalis Therapeutics�6��]�} ����Md��(4:�q�$48�*<@��K��]P�sv�l��D��O�B����
6
^Z?O[��"*`S next big thing• �QZ!X��AyL �H7)����• a�����"7?�.rh�3��96D4
�R���CRISPR�TXO[]B;�8�25;�JK�/���1�P6• ��M!i���JR�zmUrh�N����Md��'.��%��)�• eCo��=$-@,!{�,!���QU(��-1
V]P6�$�� ���'• '?�5>�S��u�fE3F��bET�• 2��"%1=$-@,���:N380M@!~��9$>,1�@�W
<�H7GUI>�E=G�b�#�&/��+�0• tZ���[L� n|��_�"/7)$2!pO• 2019.12Z��_YC!T`
La>\WG���$�'.�1• ga�������cHrh����^j• 5C�bE6$7=$@��2C�GF6$7=$@!Vk
FA���*��'• Xx�w�93+;@1.�:�hP�I�)$&@0#,1
fE�\�YF�]�
)
7
• ••
• ( ),
•PRISM
BioLab
CEO
• ( ) CEO, ( ) , ( PwC Strategy &),
( ) •
••
MD PhD: SVP, Chief Technology Officer
• ,
• Joslin Diabetes Center( ),
• Medical Patent Research ( )• ) ( )
, ( )
MBA: SV, Chief Financial Officer
• ( ), ()(CFO), Argenes( ), ,
•
Joseph S. McCracken• Roche , Genentech,
Sanofi-Aventis
,�) 2%6[=2%6+�.4�8�A?2%6+�.4�8�*�-5#'2%6
8
b=�R�,�) 2%6
*1: P21��|�c�*2: WFX �K{���xV\h���iu
+�&(����JC
ZQJC
"��#&�IS�@S
GNDM.7&"�.�w
GNDM� $1�PyL
Na2%6���`d
G}�rvGMPpq
�12�24�B�
G}� }�
]s�3�109� pq�tY
[=2%6+�.4�8
jDrvJC�/�6 &8iE
4�!8 �JC/�6 &8iE
4�!8 �7�36$�iE*2
4�!8 �!�6 /�6 &8iE*2
Na2%6���`d
U�fk�g_T*1���oQ�n;le
jDrv
4�!8 zM
zM<F>
jDrvJCzM
jDrv�zM<F>
A?tY�leT
A?2%6+�.4�8
O~:�^m 4�!8 ��&�"�08��IH
Gd6�ZTC���(�)+�-
9
I1nB�Gd6�ZTC���(�)+�-
��������
�&
MDL-201
MDL-202
MDL-204
MDL-205
MDL-206
oeXV*
hl
hl
.pL=
.pL=
.pL=
(�%'�EA74 5ckPW ckPW
DI< DII< DIII<jm UY 5ck IND
F1*$,
MDL-101
MDL-102
MDC1A
.pL=
32
32
32*$,
*:]86�_OoeH��0i��Ma>7�����SQ/�9N��\7K���?f�^:�������F1*$,(�)+-�`;/�@b\7K��������Jg���� �
���380��� ���������
�"#+"R[
�"#+"R[
�"#+"R[
�"#+"R[
��!�
�������
10
0 1865
645
46
141
213
146
2016/12 2017/12 2018/12 2019/12
2
6
10131
1
4
2016/12 2017/12 2018/12 2019/12
2019
11
US
)PhD7
(JP
)PhD5
)PhD7)PhD2
33 109
218
304
2016/12 2017/12 2018/12 2019/12
(
12
( ) 2018/12 2019/12 2020/12 1Q1,214,738 3,874,974 3,703,9381,205,143 3,857,235 3,682,880
757 48,954 51,7639,011 14,499 14,199
1,224,508 3,938,428 3,769,90122,728 95,885 45,44650,000 1,300,000 1,300,000
1,371,735 2,621,735 2,621,735219,640 79,112 197,398
1,202,094 3,842,623 3,724,3361,201,779 3,842,542 3,724,4551,224,508 3,938,428 3,769,901
( ) 2018/12 2019/12 2020/12 1Q65,297 644,500 13,000
279,420 487,305 129,164217,927 303,680 81,317
61,493 183,625 47,846214,123 157,194 116,164
983 1,119 98250 11,962 858
213,390 146,351 116,924213,390 146,351 116,924
O 4,518 5,823 1,362217,909 140,528 118,286217,909 140,528 118,286
( )
( )
A
:
42%
2%8%
O O12%
VC36%
A
:
37%
2%
8%
O O11%
VC32%
10%
��������
13
a]�56"+�4=_Ta]�\����.3( 2%0,RD10,000*�L���/,�a]�8��B7,000#_Ta]����80%†[XFa]�!�-3*1 �
14
KJWAUP�5�$&,�A=�15�)RD
]<I
>Va]
Z`
A
Z`
B
Z`
C
Z`
D[X?a]�95%† ¶�OY@���
a]�56"+�4
�����^Z'�#*,����]<I�N�a]
HS���B600��OYZ���
4M7¶
9G: *21st Century Cure Act, #NIH GARD †innovation.org ¶GlobalGenes.org�Active therapeutics of 491 NME, 106 BLA, 17 cellular and gene therapy products @FDA as of 2019.7.22 Source from KEGG
C;�E��Q:�_Ta]���15�)
MI9�+(.-�@N�&��%2?G�MI9���&�&+(.-��$�OU�JL!78�"��ON/OFF'@N
15
OUA
OUB
VT
,20)F
MI9X
+(.-1.)+
MI9Y MI9Z
>4�A��D3�MI9+(.-����
• P��:�<37��OU�� ��%
• "�200����%OU�5�; =C H����& 6�DNA�EQ'B���%
• ��H��30��DNA�"��*�/�&%2���������&�ON��$��&�OFF��%��OUS�KR�@N�&��%�#��%
IF6OL�HE��$�KA� �#"�KA�D8�,- �
16
��AAGTCAACTAGC��
��$0*�/B��KAE�!&%���
ON����.�OFF�������>3�!&%�;*C:������
OFF����.�ON�������13�!&%�<N��������
�'9���?@
>3�!&%�>3�+7�.�>3�C:������ �#"GM�4J�����
2)�5��=(�IF6OL�HE
�/�-+�#, �.&*'0�"�DNA����� &*'0�"�DNA�)!�
17
�(�����$����
��AAGTCAACTAGC�� ��AAGTCATCTAGC��
.&*'0 &*'0
������%���/�-+�#,����#,�
�!"<5��=798?�/��DNA�2�& �.798?�3;�����%-���8?�>�0:
18
��AAGTCAACTAGC�� ��AAGTCATCTAGC��
��AAGTCATCTAGC��
1;
=798? .798?
+(�,��4'��!"<5����0:)
DNA�26�������$*���# ��@�
Monogenic Diseases(&'�%!�,*)����Monogenic Disease�#$ �+ -"���� �
19
Monogenic Disease�'
=1 %!� �( �
�'1
��'2
�'3
�'4
�'5
�'6
�) ,*
�� �������� ��,* Monogenic Diseases
=>*<90C@� ��%#-�A5���,'? ���3:; �"+
20
7,000 ���
3,500 =>*<90C@
2,200 �����������
=>*<90C@ <9*3:,';�)B(1989~ �����)
!1: Discovery Medicine�4�Modalis Tx62
.&�/��7$�.&�(8C@ ���������TAM
!1: The Journal of Gene Medicine (2019)�4�Modalis Tx62
66.8%11.7%
Cancer diseases
Monogenic diseases
Cardiovascular diseases
Infectious diseases
Others
Healthy volunteers
Neurological diseases
Gene marking
Ocular diseases
Inflammatory diseases
ho\C=�JK�/�-4GTx��PoP�PoC�C=�cI�R<_YN�>�
21
8s�Smo
3!.'2(Proof of Mechanism)
zfDX(Proof of Principal)
$6(1,DX(Proof of Concept)
15*",�)�#+,;A�vdB��WF��
15*",�ia�? �oE@�WF�Z��
15*",�rw@�Ln���WF�ia�q���
oUGa 15*",�)�#+,uk�xj��PhIIb
PhIIa
PhI
pre
clinic
al
plASmCRISPR-GNDM
��������
�rw^g�Qt���y�����
pre
clinic
al PhI
b;A��0� 5%+"&�C=/�-4
7O: Nature Biotechnology volume 30, p596–599 (2012)�V�Modalis TxWP
H:�M��]9�GTx�`e[TN
GTx�E������1 /"9KGTx�E�������LM������ /"���5I���
22
!.: Evaluate Ltd�2019�8$'0���� ;�CAGR�2018��2024���2G/"8�5I?�2019�2024�*
27 4441,371
3,060
5,820
10,062
14,906
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
2018 2019 2020 2021 2022 2023 2024
CAGR 185.7%341 5I 14.9 Billion$(2024�)
2,0402,693
3,4964,336
5,795
8,051
10,651
0
2,000
4,000
6,000
8,000
10,000
12,000
2018 2019 2020 2021 2022 2023 2024
120,563135,722
149,757163,136
176,325187,211
197,215
0
50,000
100,000
150,000
200,000
250,000
2018 2019 2020 2021 2022 2023 2024
399,725399,874
416,784 444,066475,819 508,220
545,585
0
100,000
200,000
300,000
400,000
500,000
600,000
2018 2019 2020 2021 2022 2023 2024
CAGR 31.7%341 5I 10.7 Billion$(2024�)
CAGR 8.5%341 5I 197.2 Billion$(2024�)
CAGR 5.3%341 5I 545.6 Billion$(2024�)
US $ (mln)
US $ (mln) US $ (mln) US $ (mln)
D@(6B�Gene Therapy�341 /"5I
AJ=C(DNA&RNA therapeutics) H+=C(Monoclonal antibody) :%(=C(Small molecule chemistry)
,#�-��7"�GTxF�)&><
GTxS4 M&A6i2018�20192 M&A$��.���g]/K>O[�JM�J^M<&.cl�I;
23
S4Q �0��9C g]N/K> g]/K>O[ bX�pk:Pm���DE=8\�
2019/12 3.0 billion$AT132: NeGX@}wf,�("�(XLMTM)AT845: *1�hAT702, AT751, AT753: $-��1'jw��%0)��(DMD)
2019/10 3.0 billion$(�)
SPIRO-2101: ��GdtySPIRO-2102: ��Gdty
2019/6 1.0 billion$ $-��1'jw��%0)��(DMD)wFYG��%0)��1j(DM1)
2019/3 165 million$ MYO-101: �ojw��%0)��2E j(LGMD 2E)MYO-102: �ojw��%0)��2D j(LGMD 2D)
2019/3 800 million$NSR-REP1: A�x��uy��0�$/,��NSR-RPGR: X@}G{�rs`Gy(XLRP)NSR-ABCA4: �!#��&h
2019/2 4.3 billion$SPK-9001: vnhBSPK-8011, SPK-8016: vnhA SPK-7001: A�x��uy(�0�$/,�)
2018/5 8.7 billion$ .�1�+AVXS-101�IT�: ��Gw�uy�j�SMA Type 2�AVXS-201: /#%yqz�RTT�AVXS-301: wUuGZ|~?y�ALS�
3H: a7=WTL�R�ModalisTx�VI
B7 F��_5�GTxS4 M&A6i
�������
���� ��
VERTEX
SAREPTA Tx
Biogen
Roche
NOVARTIS
AUDENTES Tx
ROIVANT
Exonics Tx
Myonexus Tx
Nightstar Tx
Spark Tx
AveXis
CRISPR�/��!%H;>C=<.,�+4=8�RNA������#� ��&�$���9��1/��!%H;>C
24
CRISPRF5��!%H;>C
ZFN TALENCas9
gRNA
ZFN TALEN
0?-�AJ�RNA�DNA�6E�
(7���KG)
2*�3��:)��!%H;�CRISPR>C� ��
�'"��I�B@D�
DNAAJ�6E�(7���(<)
0
10
20
30
40
50
60
70
80
90
100
Jan-04
Jan-05
Jan-06
Jan-07
Jan-08
Jan-09
Jan-10
Jan-11
Jan-12
Jan-13
Jan-14
Jan-15
Jan-16
Jan-17
Jan-18
Jan-19
CRISPR @+*�5
25
RNAi
iPS
CRISPR
67%
23%
10%
86%
7%7% JPNUS
RNAi ����F3FOct 2006
iPS ����F3FOct 2012s
Google����8I������ (EG)DA(,67) ����3?B 8IK0 &C;%H(2005-2015)
.# /��<"�,67@+�=��CRISPR
!0: Google Trends�9�ModalisTx�:1@: iPS 8I������42012�10$(2�100���( -'>J
iPS CRISPR RNAi
�,����CRISPR.0= CRISPR-GNDM�52'������)6� +4�%�
26
CRISPR-GNDM (Guide Nucleotide-Directed Modulation) platform
dCas9(������)
�� �ON/OFFgRNA
������
��,���� �!
��� 38 7/1 )6
������
(&�*��-$�CRISPR-GNDM�#���"
CRISPR-GNDM��!"��AAV����+'�������&*!��
27
1 2 3
AAV����
AAV������ ����')��#��!
GNDM�����&(�"$
4
U6 Cas9gRNA pA
+GNDM
-GNDM
(# %�)����$��
���&(�GNDM�� ����%
������ ��CRISPR-GNDM�!"��
� GNDM����*),���!��"&�0���%��-����gRNA������'�#��" -),����
28
gRNA
ON1
OFF1
dCas9 �������
2/�3��4.�CRISPR-GNDM�4. ���*(+$�
• (X^1: 1 / 30,000*• ONLC: ������• (X*6 : [)*����������0��• SZXE:=]�V.G/VUHG/XW�'(+A3-YDL?42�\B
• :TPK• =]�SZ+7;����� �������
• ON+5Q: LAMA2ON, DR
MDC1A(>F8V���$���1AM)LAMA2 ����������������� ��������
&9: IJ@<�%�����Flores et al, Frontiers in Molecular Neuroscience vol 13 (2020) *Ophanet�
����!�#�MDL-101�� "�%��
29
������ GNDM�MDC1A�,�1204�3� ��LAMA1/.(������ON��
dCas9
CRISPR-GNDM-a targeting LAMA1
���RNA
���������
LAMA2
1204
+-*)
12������ ����3� ��
"� �$�&�MDL-101!�#%�'���
ON
LAMA1
30
Small 3.5kb Large
6l�fb=NdB780vm
cr`d�B520vm/siRNA/ASO�
tqLE
GNDM�;[���a_>Z�GTx�eI�#).iT��N���fbGvm�/!4�*!+0!4�n5
31
#).iTm9� A
m9� B
m9� C
Gain ofMalfunction
�kZCP�pO�
Loss ofFunction
�JZCP�u\�
B400]�-3!(%,�%
: fb=�vm��"0��wHk���������������
5H: hj=fbGvmK�Discovery Medicine���gvmK�Modalis TxA�
GNDM�g8��6X�Q��fb=�%!'&�$4(2�1��W^����eI�Nd?��N����-3!(%,�%�@s�VP���
hj=fbGvm B3,500vm
GNDM�2,200��� ���
tq
GNDM�;[a_ eI�#).iT�YMUkwH
fb=<�Ro������1����������
D8�F��S7�CRISPR-GNDM�;[a_
�������
32
ModalisQ�h�1$37+.6,8J>6,8�UG���HB��SY�A@6,8�#+4'$.!c��T��� E�
33
[C��4:*&-��^L ���
J>6,8 1$37+.6,8
M]�k��0%1%�Xe
g��d�R
<�#+4'$.�a��
Z��?�R
<�SY�_f
e.g. �����
A@6,8
e.g. �����
UG�39�&$�3;
SY�WO�
V: =K������$5�(\����F@�`I�>b!Ni�j���!DP����������"
2(/)6,8�1$37+.6,8
LX�TWF3*�.�UC�)�.� �0L7�H���Z�=6M?�%� "��QP
34
�� ����
�������+
���������+
���������
����
F3*�.%�(,�0�LX 54*�.%�(,�0�LX
B4LX
GY/�+-��*
VWAJ
GY/�+-��*
%� "�EX
VWAJ
&�#�*�.�$�'-�!*�.�LXTW
�,��0��0(S7)�IR�8J� IR>K@<�8 1;9D1�2:ON�GY������
(3� ���Broad58!.#�CRISPR&�->���.#�%/B?->�����24+�
����
�1�����
A;76
CART
@&,:
<9��=
�!�0��*'$&�Modalis Tx)"
GNDM IP
35
���(3� ���
��� ��-��(3� ���
Editas Medicine����
�� ���
MIT
����
������������
������
Allerganabbvie
JUNO TxBristol-Myers Squibb
Beam Tx
�#��&�HT���%!���DMD��4,>S2024'��RK3?PQCF�83,000=5DN�4,�;* �-6�
36
(:�Evaluate Ltd�@�Modalis TxB;�2019'8+1<���� *: Orphanet��E�2019�2024'7�>SI�DMD�MDC1A�0�T���%!���)L�MDC1A�.UW7�DMD�1/3~1/10J7�O2
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
2018 2019 2020 2021 2022 2023 2024SRP-9001 (AVII) Raxone (SANTH) Exondys 51 (AVII)Golodirsen (AVII) Vamorolone (SANTH) Casimersen (AVII)Translarna (PTC Therapeutics) Suvodirsen (WAVE Life Sciences) Edasalonexent (Catabasis Pharmaceuticals)NS-065 (NIPSH) Other
US $ (mln)
RK3?PQ
MVGQ
�3,000��
���"�$��#��&�HT���%!���DMD��4,>S
.UW7:A9(/� 1/3,500-1/9,300 *
������$1,484M�������EDIT-US�
CART���3 �����4@ws�k�
nE6$25M+ eg^$22M + *�/!&�1$700M
'(#LCA10
5�� ����nE6$90M + MS�0�,.$�
������$1,099M�������NTLA-US�
CART!�$%�"&
$10M�nE6� + $20M�bd&-1!)���+ $20M�eg^�+ $230.3M�*�/!&�1 / 1 product�+ 15%=<�0�,.$��$13M\_t:& Novartis��DDS�A��14`p�-�#1!
Option for10(# ����& Except some
$75M�nE6�+ $135M�*�/!&�1 / 1 product�+ 10%=<�0�,.$��$50M\_t:@ IPO
������$3,654M�������CRSP-US�
Option to 6 targets$75M�nE6�+ $30M�`pHLTc�+ $420M�MS / 1 target�+ 0�,.$�
JV�� 50:50 & $70M\_t:
$%(#���(#
BAYER�CASEBIA�$45M�nE6� + $255M�eg^�
CASEBIA�CRISPR�$15M�nE6��$20M�when get IP�
o87fCRISPRbd�N�29S538�ru:�=� ���CV�%��/�JB
37
$747M
$293.3M
$260M
$525M
$405M
3I�a8DZUM�R�Modalis TxXJ�;WP]�6/12;K *%��/��"�GF�����*�/!&�1qnE6]m�\_t:�P]
YiO Yi>[ %��/>v %��/��"
( '!+%/�lh?Qj�-�#1!7f
Editas Medicine
Intellia Tx
CRISPR Tx
JUNO TxBristol-Myers Squibb
Allerganabbvie
NOVARTIS
REGENERON
VERTEX
BAYER
CASEBIA
CRISPRIH���%�'��#-�(�VN�1�2;8>�= �O0�B���!�#+�.�WQ��)����$��*.�DS
38
F�K�JCR�64:/��6/3272;8>�7CR�EG?:/��G?;<�B=Billion
Canonical(5U3=P@)
Non-canonical(���)
$3.9B
$1.5B
$1.4B
$1.1B~$1B
~$1B
?
Dx�TAM� Platformer Tx
�9LM�
"� �&�,�CRISPR�%�'�#-�(�
Intellia TX
CRISPR Tx
Editas
Beam Tx
KSQ
ExonicsTx
CASEBIA TX
BlueRockTx
VERTEX
BAYER
SHERLOCK BIOSCIENCES
Mammoth Biosciences
����
39
���)�������&���*���(��%#
40
��������*
�������&�
MDL-201
MDL-202�������!��*���
MDL-101
MDL-102
MDL-204
�������� #
�2,200+(� ���'�����
������������$�
MDL-205
�"+(%$�&�
���)�������������$�
100����� ���+(��)
MDL-206�"�380!� �� ����'�
4'#�%�� $�&:8�D1�!&��5*���"�%���&�!&�*
41
*5*���"�%���&�!&��J273����AF ?�>O���@;0����
MDL-201
MDL-202
MDL-204
MDL-205
2019/12 2020/12 2021/12
2019 1Q
���$�BH��$��&�L.Q6
2021
IND,I
2019 3Q
���$�BH��$��&�L.Q6
2021
IND,I
2019 3Q
���$�BH��=)CE+<
2020 ��
���$�BH��=)CENS5*
2019 4Q
������=)CE+<
TU
TU
CNS
CNS
���
K?VP
1(/R�9G-M�J25*���"�%���&�!&�
MDL-206
CNS2020 2Q
���$�BH��=)CE+<
��380����
$#�� �����!/%����� ���!��!�*
42
*/%����� ���!��!��;-1.����78 5�4?���63+����
MDL-101
MDL-102
2019/12 2020/12 2021/12
2020
���!�=)A0/%
2022
IND&:
2021
�����!(
MDC1A(CD)
CNS
CNS
���
<5E@
,"*B�29'>�;-/%����� ���!��!�
2021
���!�=)A0/%
MDL-103
GNDM������������
• +;��������B? 0��• "& 6 ��*!(�
• '8&>��/+*A23�.#��79����• 5)��� @<
• �����= B?�-,:%41• ������%$
43
}��h�VO�
�� yOT #E0��85%* �X rQ�
��}���Th����}�
���%#�CRISPR�
1�- >(B
&$(��������)
��(5D$�))
��fz�k��bm`�
HSJP/��7E%?���~[L I�d��s���T�u5@&)3��<�e/��7E%?�
44
JP/��7E%?����
K\����qx/��:E A�6M��vLWplc�j�Modalis Txo] Rngt 6/15R^|�1990Ga�JP�/���;@��i_��w��}�Z��7E%?�����=�E0�5@�E�j�}��h�V�O�
�4587���������! "�6,276��
�������
�4565���������! "�1,301��
+.�?A�
UFI�YHMT
3�,&� /��
�B+/�����E =(��./
@��A���
�?E/ DWTI
�N{�
Delta-Fly Pharma
GNI�E/��{�
"C����3��:
JCR3��:
�E�!@2�����E
A��(���:)A&�
4@�)0 �/��
'<A<
��E'�.���E
���<�/�����E
�E/��
6A�
J�TEC
!B��*
#�@/��
=(�-&)A5D!B!B"�
�E��
A9;&�
�E�A /��3��:
=*C&�
Appendix
45
Modalis�9C���)��� �#��#�24(0A6�DG
46
• 2022*+�/.#&�%$���1 �USSWHN3�����9C�
• #&��!RJF�T@5�82OQ�B�,��
• K47�IM�21�;�E��#%�!"��$�>:�7��%��'��T@5�LU��
?-<V�+-=5�9P
������(��������%&'!
47
������$���� ��"�%&����#
������������
����,+#�DNA,+#�����(����)! DNA(���) ����%'-&(�����) ��
48
*$ ./�� ./�"�����)(���
./ ���
84(/5����0%&)*,����*'���!������:@�84(�>��
49
�����84(0%
<?:@�9+
73��:@��;"��*'�
2 strategies for gene therapy1. Ex vivo 2. In vivo
84(�� ��� �$#
-�����DNA�=���������.1
-2�84(
84(/56����/5)
GD�*E
(P>�)GD�*E ���I6E�
QMSK - ZFN TALEN CRISPR CRISPR CRISPR
SK&) - RL��@� RL��@� 4�#��� 4�#��� 4�#���
1#��� '?GD��=�
���I67C"J ���I6 ���I6 1N+3F 7C"J
� �� AAV/LNP AAV AAV AAV/LNP AAV/LNP AAV
0:�29 2 2 2 2 9(1N+3F) 9
�8GD�� ~3.5kb " � " � " � " � " �
-�B
GNDM�GTxH��<A;O
50
�$ : !�.(�,ModalisTx�/%
CRISPR-GNDM�5� <A;O
AUDENTES TxSpark Tx
AveXisSAREPTA Tx
REGENXBIO
Sangamo TxEditas Medicine
Intellia Tx
CRISPR Tx
Beam Tx
T�u�1/2�
51
Page Word Explanation
P9 MDC1Af�\�238E>*�1A��B@:Fα2(0�9�%��PLama2�w��"��_ ���&%
P21 GTx Gene Therapy���Pg��
P24 ZFN�2F.>*F-�;.D)�4� /<A�u�bIcV�/<A�u(�%���HkO�]e�&��SO�DNA�G�(n{�%Hk[�¢��5F=.��
P24 TALEN�5DF� /<A�u�blcV�ZFN�h}���%y��PTAL effector�TALE�(d�Hk[�¢��5F=.����O������DNA��(���n{�������x��
P24 gRNA�-+9RNA� CRISPR-Cas136A���P��s�\(�%���oT�&%`r�i�RNA
P26 dCas9Q��DNAn{p\(q�%Cas9(¢�p\(�'�%w�(~L��n&��Cas9��� �
P27 AAV?.5�H!�J��t��%)7<��,+C3(T����P~LMR�aN�T�#&���)7<,+C3?.5�!D8E,+C3?.5��|�����¡X\����ZU\�K���&��$�^vYz���P~LMR
P31 Gain of Malfunction ��Wm�jw�
P31 Loss of function Wm ��w�
T�u
Nma�2/2�
52
Page Word Explanation
P31 siRNA 21-23�ZE��V�iAI[>�RNA����RNA�v B� �-�&/2xsI(mRNA) n��MGxsI�R_ k� �FK
P31 ASO Antisense oligo(!=.+=*$:')�wGh��OdG��@>��DNA���RNA�siRNACr�MGxsI�R_ k� �FK
P36 Duchenne muscular dystrophy 19(#=3q�)*2<6"��)*2<6"=xsI�|f����B���)*2<6"��@t
P41 CNS Central nervous system�?�]P���QY��}�����T��
P48 5*2=3%;$,�8 ����^uBY�`J��%<7.=�Z>GgVzX�xsI�\�b�SuBY(4%0:!)�E��^uBY��DNA�����go �����
P48 %<7.=�� 5*2=����������%<7.=go y���b�goL�����{L pV��
P49 Ex vivo / In vivo Ex vivo�LU�xsI�� ~��cD�cD��~� LH�We��FKIn vivo���l��� P�EjAI ~�H�cD��FK
Nma